Literature DB >> 16929532

In vivo quantification of delayed gadolinium enhancement in the nucleus pulposus of human intervertebral disc.

Jaakko L Niinimäki1, Outi Parviainen, Jyrki Ruohonen, Risto O Ojala, Mauno Kurunlahti, Jaro Karppinen, Osmo Tervonen, Miika T Nieminen.   

Abstract

PURPOSE: To quantify the delayed contrast agent enhancement in the nucleus pulposus of the intervertebral disc by means by T1 relaxation time measurements, and to correlate the enhancement with visual grading of disc degeneration. Diffusion of nutrients through the endplate is a key factor in tissue viability in the intervertebral disc. It can be simulated in vivo using magnetic resonance imaging (MRI) by measuring delayed gadolinium (Gd) enhancement of the disc.
MATERIALS AND METHODS: Twenty male volunteers underwent a lumbar spine examination at 1.5T. T2-weighted sagittal images were used to score disc degeneration. T1 relaxation times were measured before and 90 minutes after intravenous administration of Gd-DTPA-BMA by applying a series of sagittal single-slice inversion-recovery fast spin-echo (IR-FSE) scans.
RESULTS: A total of 93 discs were analyzed. A statistically significant decrease in the T1 relaxation time of the nucleus pulposus was observed as a result of contrast-agent intake. The percentage change in the T1 relaxation rate for individual discs was up to 126%. A positive trend was observed between the change in the T1 relaxation rate and the grading of disc degeneration.
CONCLUSION: Quantification of delayed enhancement of the intervertebral disc may provide a new means of studying alterations in degenerative disc disease (DDD) that explain the variation in diffusion into the intervertebral disc. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16929532     DOI: 10.1002/jmri.20693

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Advances in Magnetic Resonance Imaging for the assessment of degenerative disc disease of the lumbar spine.

Authors:  Chenyang Wang; Joshua D Auerbach; Walter R T Witschey; Richard A Balderston; Ravinder Reddy; Arijit Borthakur
Journal:  Semin Spine Surg       Date:  2007-06

2.  Association of lumbar artery narrowing, degenerative changes in disc and endplate and apparent diffusion in disc on postcontrast enhancement of lumbar intervertebral disc.

Authors:  Jaakko Niinimäki; Arto Korkiakoski; Outi Parviainen; Marianne Haapea; Mari Kuisma; Risto O Ojala; Jaro Karppinen; Raija Korpelainen; Osmo Tervonen; Miika T Nieminen
Journal:  MAGMA       Date:  2008-10-24       Impact factor: 2.310

3.  Validation of sodium magnetic resonance imaging of intervertebral disc.

Authors:  Chenyang Wang; Erin McArdle; Matthew Fenty; Walter Witschey; Mark Elliott; Matthew Sochor; Ravinder Reddy; Arijitt Borthakur
Journal:  Spine (Phila Pa 1976)       Date:  2010-03-01       Impact factor: 3.468

4.  The Quantitative Structural and Compositional Analyses of Degenerating Intervertebral Discs Using Magnetic Resonance Imaging and Contrast-Enhanced Micro-Computed Tomography.

Authors:  Kevin H Lin; Simon Y Tang
Journal:  Ann Biomed Eng       Date:  2017-07-25       Impact factor: 3.934

5.  A novel technique for the contrast-enhanced microCT imaging of murine intervertebral discs.

Authors:  Kevin H Lin; Qi Wu; Daniel J Leib; Simon Y Tang
Journal:  J Mech Behav Biomed Mater       Date:  2016-06-08

6.  Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST).

Authors:  Wen Ling; Ravinder R Regatte; Gil Navon; Alexej Jerschow
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

7.  Assessment of lumbar intervertebral disc glycosaminoglycan content by gadolinium-enhanced MRI before and after 21-days of head-down-tilt bedrest.

Authors:  Timmo Koy; Jochen Zange; Jörn Rittweger; Regina Pohle-Fröhlich; Matthias Hackenbroch; Peer Eysel; Bergita Ganse
Journal:  PLoS One       Date:  2014-11-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.